Technology: Scientific Publications
2025
Knudsen, S., et al.
An mRNA-based predictor of response to Daratumumab in Multiple Myeloma
Poster presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting; 25-30 April 2025, Chicago, Illinois.
Musa, F., et al.
A phase II trial of Stenoparib (2X-121):a novel dual tankyrase and
PARP inhibitor in advanced, recurrent ovarian cancer
Poster presented at the SGO Annual Meeting on Women’s Cancer 2025; 14-17 March 2025, Seattle, Washington.
2023
Knudsen, S., et al.
A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors
PLOS ONE. 18(8): e0290681
2021
Pili, M., et al.
Clinical development of a predictive biomarker with 58 tumor genes for dovitinib treatment of solid tumors
Poster presented at the ESMO 2021; 16 – 21 September 2021; Convened Virtually
Foegh, M., et al.
A novel drug response predictor (DRP) mRNA biomarker of the tumor
response to the multi tyrosine kinase inhibitor dovitinib
Poster presented at the European Association for Cancer Research Virtual Congress 2021; 9 – 12 June 2021; Convened Virtually
2020
Stone, E., et al.
Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.
bioRxiv 2020.11.12.380394
Plummer, R. et al.
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.
British Journal of Cancer volume 123, pages525–533(2020)
Kappel Buhl, A. et al.
A drug response predictor to guide treatment for breast cancer
Pharmacogenomics, 2019 (Ahead of Print)
2019
Kappel Buhl, A. et al.
Doxorubicin response prediction in neoadjuvant breast cancer therapy
Journal of Clinical Oncology 2019 37:15
Kappel Buhl, A. et al.
A drug response predictor to guide treatment for breast cancer
Pharmacogenomics, 2019 (Ahead of Print)
2018
Kappel Buhl, A. et al.
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
Breast Cancer Research and Treatment (2018)
Vangsted, A.J. et al.
Drug response prediction in high-risk multiple myeloma
Gene 644 (2018) 80-86
Kappel Buhl, I. et al.
Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
PloS One 2018; 10.1371
2017
Kappel Buhl, A. et al.
Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort
Abstract no.: 1071, ASCO Annual Meeting, Chicago, 2017
2016
Kappel Buhl, I. et al.
Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer
Abstract no.: e20007, ASCO Annual Meeting, Chicago, 2016
Dreier Christensen, D. et al.
Fulvestrant response prediction from transcriptome data obtained from primary breast cancer biopsies
Abstract no.: e12056, ASCO Annual Meeting, Chicago, 2016
Kappel Buhl, I. et al.
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
PLoS One. 2016; 11(5): e0155123
Winther, M. et al.
Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophagual Cancer
PLoS One. 2016; 11(2): e0148070
2015
Knudsen, S. et al.
Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL
PLoS One. 2015; 10(2): e0115538
2014
Knudsen, S. et al.
Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients
PLoS One. 2014; 9(2): e87415
2013
Wang, W. et al.
Independent validation of a model using cell line chemosensitivity to predict response to therapy
J Natl Cancer Inst. 2013; 105(17): 1284-91
Carlsen, AL. et al.
Cell-Free Plasma MicroRNA in Pancreatic Ductal adenocarcinoma and Disease Controls
Pancreas. 2013; 42(7): 1107-1113
2012
Bullinger, L. et al.
Results of a phase I/II trial of belinostat in combination with idarubicin in AML – favorable impact on mainly intermediate cytogenetic risk AM can be predicted by gene expression profiling
Presented at ESMO 2012, Vienna, Austria
2011
Chen, J. et al.
A 71-gene signature of TRAIL sensitivity in cancer Cells
Mol Cancer Ther. 2011. 10.1158/1535-7163
Miller, I. et al.
Market access challenges in the EU for high value diagnostic tests
Personalized Medicine. 2011. 8(2): 137-148
2010
Patnaik, SK. et al.
Evaluation of micro-RNA expression profiles that may predict recurrence of localized stage I non-small cell lunger cancer after surgical resection
Cancer Res. 2010; 70(1): 36-45